Balaji Gandhi Sells 4,687 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 4,687 shares of the firm’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $16.36, for a total value of $76,679.32. Following the sale, the chief financial officer owned 150,569 shares of the company’s stock, valued at $2,463,308.84. The trade was a 3.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Balaji Gandhi also recently made the following trade(s):

• On Thursday, January 15th, Balaji Gandhi sold 975 shares of Phreesia stock. The shares were sold at an average price of $16.38, for a total value of $15,970.50.
• On Thursday, January 8th, Balaji Gandhi sold 8,009 shares of Phreesia stock. The stock was sold at an average price of $17.01, for a total transaction of $136,233.09.

Phreesia Stock Performance

Shares of PHR opened at $15.59 on Thursday. The company’s 50 day moving average price is $17.94 and its 200 day moving average price is $23.03. Phreesia, Inc. has a 52 week low of $15.40 and a 52 week high of $32.76. The company has a market capitalization of $939.62 million, a PE ratio of -155.83 and a beta of 0.61. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44.

Phreesia (NYSE:PHR) last released its earnings results on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.11. The company had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The company’s revenue was up 12.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.25) EPS. Research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Key Headlines Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Recent operating results show improvement: Phreesia beat consensus EPS and reported revenue growth (quarterly revenue up ~12.7% year‑over‑year), supporting the business case for recovery at current multiples. MarketBeat PHR profile
• Positive Sentiment: Wall Street remains largely constructive — most analysts rate PHR a Buy and the consensus price target (~$30) is well above the current trading level, giving upside if growth continues. Analyst consensus
• Neutral Sentiment: Although insiders sold sizable blocks, each still retains a material stake after the trades (examples from filings: Evan Roberts ~826k, David Linetsky ~224k, Allison Hoffman ~170k, Balaji Gandhi ~150k, Amy Vanduyn ~159k), which may temper concerns about a loss of long‑term conviction. InsiderTrades summary
• Neutral Sentiment: Market context: volume is slightly above average and the stock is trading below its 50‑ and 200‑day moving averages and near its 52‑week low — conditions that can amplify moves but also offer a potential entry if fundamentals improve. Price performance
• Negative Sentiment: Coordinated insider selling is the primary near‑term driver of weakness: multiple senior executives sold on Jan 15–16 at ~ $16.36–$16.38 (combined ~29,511 shares). Visible, same‑period sales by several officers can prompt short‑term selling pressure as other holders react. Evan Roberts sale (example)
• Negative Sentiment: Insider sales may be interpreted as liquidity or diversification events rather than vote of no confidence, but absent clarifying disclosure (e.g., 10b5‑1 plans, option exercises) the market tends to treat clustered insider sales as a negative signal. SEC filings

Institutional Investors Weigh In On Phreesia

Large investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC lifted its holdings in shares of Phreesia by 243.6% during the second quarter. Squarepoint Ops LLC now owns 100,922 shares of the company’s stock worth $2,872,000 after buying an additional 71,553 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Phreesia by 9,375.0% in the second quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock worth $86,000 after acquiring an additional 3,000 shares during the last quarter. Arcadia Investment Management Corp MI increased its position in Phreesia by 22.3% during the second quarter. Arcadia Investment Management Corp MI now owns 113,470 shares of the company’s stock worth $3,229,000 after acquiring an additional 20,700 shares during the period. Acadian Asset Management LLC raised its stake in Phreesia by 61.6% during the 2nd quarter. Acadian Asset Management LLC now owns 364,194 shares of the company’s stock valued at $10,357,000 after purchasing an additional 138,877 shares during the last quarter. Finally, Boston Partners raised its stake in Phreesia by 165.1% during the 2nd quarter. Boston Partners now owns 130,060 shares of the company’s stock valued at $3,702,000 after purchasing an additional 81,006 shares during the last quarter. Institutional investors own 92.10% of the company’s stock.

Analyst Ratings Changes

PHR has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phreesia in a research report on Friday, October 31st. Barclays dropped their price objective on Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, December 16th. Truist Financial set a $24.00 price objective on shares of Phreesia in a research report on Thursday, January 8th. Royal Bank Of Canada assumed coverage on shares of Phreesia in a research report on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 target price for the company. Finally, Needham & Company LLC restated a “buy” rating and set a $35.00 price target on shares of Phreesia in a research note on Monday, December 8th. Seventeen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $30.06.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.